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Zusammenfassung
Hintergrund: Paravasate sind seltene aber bedrohliche
Komplikationen einer chemotherapeutischen Therapie
mit Zytostatika. Einige Chemotherapeutika haben eine
hohe Toxizität (gewebsnekrotisierende Zytostatika),
manche dagegen nur eine gewebsreizende Wirkung.
Cyclophosphamid gilt als ein nicht-gewebsreizendes
Chemotherapeutikum. Fallbericht: In diesem Fallbericht
wird zum ersten Mal ein Fall mit einer bedrohlichen
Gewebsnekrose nach einem Paravasat mit Cyclophos-
phamid bei einer Patientin mit Mammakarzinom vor-
gestellt. Schlussfolgerung: Jeder praktisch onkologisch
tätige Arzt sollte mit der potentiell gewebsnekrotisieren-
den Wirkung eines Paravasats mit Cyclophosphamid
vertraut sein. 
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Summary
Background: Paravasation is a rare but severe complica-
tion of treatment with cytotoxic agents. Some anticancer
drugs are considered to be of high toxicity (vesicant),
some are merely irritant, and some are regarded as
nearly non-toxic to healthy tissue as is the case with cy-
clophosphamide. Case Report: In this report, we present
the first case of severe tissue damage caused by a par-
avasation of cyclophosphamide in a breast cancer pa-
tient receiving chemotherapy. Conclusion: Therefore,
every attending oncological physician should be aware
of the possibility of severe tissue damage as a conse-
quence of cyclophosphamide paravasation.
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Introduction
Today, it is the standard of care for many cancer patients to re-
ceive chemotherapy in oncological outpatient clinics in an am-
bulant setting. To standardize treatment procedures, distinct
guidelines exist in various hospitals all over the world [1, 2].
The aim of these guidelines, besides the safe administration of
toxic medical agents, is the prevention as well as the correct
and effective handling of incidents such as paravasation [3].
However, these are no validated principles but are rather
based on empiric data and results from animal models [2].
Paravasation is a rare but severe complication of treatment
with cytotoxic agents. The frequency of paravasation events is
estimated to be between 0.6 and 6% [1]. Training of both the
nursing staff and the attending oncologists is very important
to minimize the incidence of iatrogenic patient injury [3].
Therefore, in the event of extravasation of chemotherapeutic
drugs, every oncological staff member who is in contact with
the patient should know how to react. Emergency treatment
procedures vary and depend on the characteristics of the anti-
neoplastic agent administered [4].
While the toxicity of vesicant agents (e.g. vinca alkaloid deriv-
atives and anthracyclines) in healthy tissues is relatively high,
cyclophosphamide is considered a comparatively non-toxic
drug [5]. However, in this report, we describe a case of severe
tissue damage due to paravasation of cyclophosphamide in
order to alert every attending oncological physician to the
potential toxicity of this cytotoxic agent.
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Case Report
A 50-year-old, gravida 3, para 3 woman was admitted to our hospital with
recently diagnosed primary breast cancer. Skin-sparing mastectomy [6]
with immediate reconstruction and sentinel lymph node biopsy had been
performed at a district hospital near her hometown several weeks ago.
The histopathological stage of the tumor was pT1c (m), pN0 (0/1sn), G3.
For adjuvant cytotoxic treatment, the patient had decided to come to our
hospital. Therefore, the planned procedures were discussed with her in
detail, and she gave written informed consent to participate in the adju-
vant SUCCESS trial. The antineoplastic regimen in this study comprises 
3 cycles of FEC (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2,
cyclophosphamide 500 mg/m2) followed by 3 cycles of Doc (docetaxel 
100 mg/m2) mono vs. DocGem (docetaxel 75 mg/m2 combined with
gemcitabine 1,000 mg/m2) [7].
Having accomplished all required preliminary examinations, the patient
received the first chemotherapy cycle at our oncological outpatient de-
partment. After administration of the entire doses of 5-FU and epiru-
bicin, we checked the position of the peripheral venous access and admin-
istered approximately 50 ml of sodium chloride (NaCl) solution as is com-
mon standard in our hospital. After ensuring that the venous access was
placed correctly and there were no signs of extravasation, we started the
application of cyclophosphamide. Near the end of the cyclophosphamide
infusion, the patient presented with pain and a tumescence on her left
forearm, seemingly caused by paravasation. The infusion was stopped im-
mediately, and supportive counteractive measures were taken: An at-
tempt was made to remove the medication by aspiration from the site on
the forearm where the peripheral venous access was located. This was,
however, unsuccessful, so the extremity was cooled and placed in an ele-
vated position. The patient was kept under observation for several hours
by the end of which she showed no pain, loss of function or any other vis-
ible abnormalities on her arm or hand. She left the hospital intending to
return the next day for check-up. The following day, she presented with a
swollen and edematous forearm but still without pain. However, 1 day
later, the patient developed a searing pain in her forearm and wrist and
was referred to a team of hand surgeons who administered pain medica-
tion and symptomatically treated the arm and wrist by applying a heparin
ointment and fitting a splint. Chemotherapy was temporarily stopped,
and the patient returned periodically for check-ups.
Nearly 1 month after the event, the ailment deteriorated, and 2 whitish
lesions became visible on the back of the patient’s hand (figs. 1a, b), suspi-
cious of a beginning necrosis correspondent to a grade 3 NCI common
toxicity criteria lesion, (grade 4 according to GOG common toxicity
criteria) [8]. Thus, the symptomatic treatment was continued. During the
next few months, the subjective and objective problems decreased but an
induration and paresthesis on the left hand and forearm persisted (figs.
1c–f). In addition, loss of both muscular strength and sensibility was
observed.
Discussion
Even if the administration of cytotoxic agents is performed
optimally and with the utmost care, the risk of paravasation is
always present [1]. However, it is important to differentiate
between iatrogenic complications and local adverse reactions
caused by the chemotherapeutic substance itself (e.g. throm-
bophlebitis or a so-called recall reaction) [1, 9]. A simple
method to reduce the risk of paravasation is to implant a cen-
tral venous device (Port or Hickman catheter) [1].
Analyses in cancer patients showed that paravasation of vesi-
cant antineoplastic agents, such as anthracyclines or vinca
alkaloid derivatives, cause severe damage to healthy tissue in
up to 30% [10]. Goolsby et al. [4] describe binding of the cyto-
toxic agent to specific cell structures thereby causing cell
death as a major mechanism of tissue damage following ex-
travasation. Scarring, atrophy, and chronic pain can result.
When paravasation occurs while irritant cytotoxic agents,
such as carboplatin or docetaxel, are administered, no necro-
sis will be seen [3]. Thus, in the event of paravasation with
these kinds of anticancer drugs, certain procedures to mini-
mize the damage have to be performed immediately [11],
even if the patient shows no symptoms [2]. However, these
guidelines are merely empiric due to a lack of prospective
clinical investigations: i) The infusion should be stopped at
once. ii) As much of the medication as possible should be re-
moved by aspiration with a syringe. iii) The affected area
should be cooled unless vinca alkaloid drugs have been ad-
ministered in which case it should be kept warm (e.g. by appli-
cation of warm compresses) [2]. The underlying effect of the
cooling procedure is vasoconstriction and thus inhibition of
diffusion of the toxic agents into the healthy tissue. On the
other hand, the purpose of heat treatment is to increase blood
circulation and thus induce dilution of the toxic agent to make
it less harmful [3]. iv) All undertaken procedures and applied
measures have to be documented very carefully. v) Vital signs
(pulse, blood pressure) should be checked every 30 min, and
the patient should stay under strict surveillance for several
weeks. vi) In cases of severe tissue damage such as distinct
necrosis or ulceration, surgical methods have to be applied,
whereas in most cases, conservative treatment is sufficient
[12]. vii) It is also of great importance to instruct the patient
to perform home self-care after an extravasation incident [2].
Today, the standard of care includes a number of antidotes
which can be used to prevent severe tissue damage: DMSO
(99% solution) is indicated for treatment of paravasation inci-
dents with anthracyclines, mitomycin C, and platinum com-
pounds for up to 14 days. Hyalurinodase can be used for topi-
cal treatment of extravasation of vinca alkaloid drugs [13]. In
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the case of doxorubicin paravasation, dexrazoxane (1,000
mg/m2) should be applied 3 times within 36 h [2, 14]. Cortico-
steroids as well as sodium bicarbonate are no longer recom-
mended [1].
In contrast, cyclophosphamide, a non-irritant drug, is known
to be less toxic in healthy tissues. Hence, in the event of par-
avasation, it is recommended to merely stop the infusion im-
mediately, remove as much of the substance as possible, and
cool the affected area while immobilizing the extremity [5].
No case of injury caused by paravasation of cyclophos-
phamide has been reported in the literature so far. Neverthe-
less, in our case report, the patient suffered necrosis with con-
secutive atrophy and chronic pain. Thus, we suggest that the
large quantity of cyclophosphamide that extravasated into her
forearm caused these major complications. At the same time,
despite all retaliatory measures taken, the cytotoxic agent
must have travelled from the patient’s forearm to the back of
her hand and cumulated there. Probably due to the high tissue
concentration of the antineoplastic drug in our case, cyclo-
phosphamide showed a so far unknown toxicity causing
necrosis and subsequent chronic pain and loss of function.
Therefore, this cytotoxic agent must not be considered safe
and non-toxic but potentially noxious and even vesicant de-
pending on the amount and tissue concentration of the ex-
travasated drug.
In conclusion, every attending oncologist should be aware of
the possibility of severe tissue damage due to paravasation of
cyclophosphamide. Since no specific antidote is known for
this cytotoxic agent yet, further investigation is needed to
reveal the toxic mechanisms of this drug when cumulated in
healthy tissue. A better understanding of the underlying tis-
sue damaging processes may subsequently lead to the devel-
opment of effective treatment and thus help preventing such
severe complications of cyclophosphamide paravasation.
454 Onkologie 2007;30:452–454 Jueckstock/Mylonas/Strobl/Willgeroth/
Sommer/Friese
References
1 Jordan K, Grothe W, Schmoll HJ: Extravasation of
chemotherapeutic agents: prevention and therapy.
Dtsch Med Wochenschr 2005;130:33–37.
2 Guideline Comprehensive Cancer Centre Ulm,
Germany (CCCU), 18.02. 2005, pp. 75–79.
3 Adami NP, de Gutierrez MG, da Fonseca SM, de
Almeida EP: Risk management of extravasation of
cytostatic drugs at the adult chemotherapy out-
patient clinic of a university hospital. J Clin Nurs
2005;14:876–882.
4 Goolsby TV, Lombardo FA: Extravasation of
chemotherapeutic agents: prevention and treat-
ment. Semin Oncol 2006;33:139–143.
5 Fachinformation Endoxan®, Stand: Januar 2005.
www.baxter.de/downloads/fachinformation/
endoxan/endoxan.pdf
6 Dian D, Hemminger G, Janni W, Friese K, Janicke
F: Management of skin-sparing mastectomy: results
of a survey of German hospitals. Onkologie 2006;
29:267–270.
7 Reich B: Individualisierte Mammakarzinom-
therapie mit Gemcitabin – länger und besser leben.
Onkologie 2007;30:70–71.
8 Cancer Therapy Evaluation Program, Common
Terminology Criteria for Adverse Events, Version
3.0. DCTD, NCI, NIH, DHHS. March 31, 2003
(http://ctep.cancer.gov), publish date: August 9,
2006.
9 Kodym E, Kalinska R, Ehringfeld C, Sterbik-
Lamina A, Kodym R, Hohenberg G: Frequency of
radiation recall dermatitis in adult cancer patients.
Onkologie 2005;28:18–21.
10 Boyle DM: Documentation and outcomes of ad-
vanced nursing practice. Oncol Nurs Forum 1995;
22:11–17.
11 Dorr RT: Antidotes to vesicant chemotherapy ex-
travasations. Blood Rev 1990;4:41–60.
12 Tsavaris NB, Karagiaouris P, Tzannou I, Komit-
sopoulou P, Bacoyiannis C, Karabellis A, Papani-
colaou V, Mylonakis N, Karvounis N, Zoannou A,
et al.: Conservative approach to the treatment of
chemotherapy-induced extravasation. J Dermatol
Surg Oncol 1990;16:519–522.
13 Bertelli G, Gozza A, Forno GB, Vidili MG,
Silvestro S, Venturini M, Del Mastro L, Garrone O,
Rosso R, Dini D: Topical dimethylsulfoxide for the
prevention of soft tissue injury after extravasation
of vesicant cytotoxic drugs: a prospective clinical
study. J Clin Oncol 1995;13:2851–2855.
14 Frost A, Gmehling D, Azemar M, Unger C, Mross
K: Treatment of anthracycline extravasation with
dexrazoxane – clinical experience. Onkologie 2006;
29:314–318.
452_454_mylonas  21.08.2007  7:56 Uhr  Seite 454
